Loading stock data…
ABEO
$5.43-0.03 (-0.55%)
Market ClosedLast close May 1
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abeona Therapeutics Inc. in the Healthcare sector is trading at $5.43. The stock is currently 28% below its 52-week high of $7.54, remaining 0.2% above its 200-day moving average. Technical signals show neutral RSI of 64 and bearish MACD signal, explaining why ABEO maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 64) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.43
Potential Upside
393.9%
Whystock Fair Value$26.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$19.57+260.4%
Range$13.00 – $28.00
Fundamentals
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$314.28M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.45
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
44.71%
Volume
Today's trading volume
681,081
Recent News
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor
The United States market has shown robust performance, climbing 3.6% in the last week and 39% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.
Abeona Therapeutics Inc. Q4 2025 Earnings Call Summary
Moby summary of Abeona Therapeutics Inc.'s Q4 2025 earnings call
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ...
Abeona Therapeutics Inc (ABEO) reports growing patient demand and significant financial gains, despite facing operational hurdles in launching its groundbreaking gene therapy.
Abeona Therapeutics Q4 Earnings Call Highlights
Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), while outlining early commercial tractio
Abeona (ABEO) Q4 2025 Earnings Call Transcript
Treating our first commercial patient this past December was a significant milestone for Abeona Therapeutics Inc., but 2026 is where the launch execution ramps up. All patient treatments and biopsies performed to date have come from the first two of our four qualified treatment centers, Lurie Children's Hospital in Chicago and Lucile Packard Children's Hospital at Stanford. This momentum provides Abeona Therapeutics Inc. an opportunity to demonstrate that the operational machine behind ZevaSkin works at scale from initial biopsy through final delivery.